Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Accelerated (9 mW/cm2) corneal collagen cross-linking for progressive keratoconus: one year follow-up

Poster Details

First Author: O. Ucakhan TURKEY

Co Author(s):    Y. Yesiltas                    

Abstract Details

Purpose:

To evaluate the safety and efficacy of accelerated corneal collagen crosslinking (CXL) (irradiance of 9 mW/ cm2; 10 minutes ) in progressive keratoconus at 1-year follow-up.

Setting:

Prospective study

Methods:

Eighteen patients (18 eyes) with the diagnosis of progressive keratoconus were enrolled into this prospective study. Uncorrected distance visual acuity (UDVA), best spectacle corrected distance visual acuity (CDVA), manifest refraction, corneal topography, slit lamp biomicroscopy, endothelial cell density (ECD) were evaluated at baseline and at all postoperative follow-up examinations. One - month postoperatively corneal stromal demarcation line depth was measured in all patients using anterior segment optical coherence tomography (AS OCT).

Results:

The mean age of patients was 24.6±4.8 years (19-34 years) and the follow-up was 12 months. The mean UDVA improved from 0.50±0.59 LogMAR to 0.41±0.61 LogMAR and CDVA improved from 0.22±0.25 LogMAR to 0.12±0.18 LogMAR at one year follow-up examination (p<0.05). The mean Kmax decreased from 55.9±6.3 D preoperatively to 55.5±6.4 D at one year follow-up (p=0.05). Mean corneal stromal demarcation line depth was 231.5±34.6 µm (range, 180-290 µm). There was no endothelial cell loss at 12 months postoperatively (p>0.05). No progression or sight threating complication was seen in any patient eye.

Conclusions:

Accelerated corneal CXL seems to be safe and effective in halting the progression of keratoconus at one year follow-up.

Financial Disclosure:

NONE

Back to Poster listing